

Nemucore Medical Innovations, Inc. (NMI), a privately-held biopharmaceutical company dedicated to the development and commercialization of nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced the appointment of Bryan Costantino to NMI's Board of Directors.

"We are extremely pleased to appoint Mr. Costantino to NMI's Board of Directors and to have him join our growing team. Bryan shares our vision for building a patient-centric, sustainable organization as NMI transitions into a clinical company," said Dr. Timothy P. Coleman, Ph.D. MBA, Nemucore's President and Chief Executive Officer and co-founder. He added, "During Bryan's tenure serving as a Partner at PwC, Bryan co-founded and ran their healthcare advisory practice which is now a greater than a billion dollar business. Bryan's knowledge will be a significant asset as we continue to grow and take NMI's nanomedicines into the clinic."

Mr. Costantino commented, "I am excited to leverage my experience to fulfill NMI's goals of commercializing nanomedicines for major unmet clinical needs such as ovarian cancer. NMI's innovative approach NMI has taken developing personalized nanomedicines has the potential to substantially improve current treatment paradigms. As NMI progresses into clinical trials, I hope to help the company realize its full commercial potential and to ensure that these life-saving nanomedicines get to those in need."

Bryan earned his undergraduate degree in Biology and Chemistry from Kansas State University and has two graduate degrees from the University of Hartford; MBA in Healthcare Administration and a Masters in Professional Accounting. While completing his MBA, Bryan worked as a Research Assistant for the Department of Dentistry at the University of Connecticut, conducting basic research for two separate studies on tissue disease and regenerative medicine. Upon completion of the MBA degree Bryan accepted a position with the Connecticut Department of Health as an Epidemiologist for their Immunization Program. Bryan held a number of other industry rolls including an audit position with the Medicare Program, Reimbursement Specialist for a hospital and a senior analyst with The State of CT Commission on Hospitals and Healthcare.

Bryan began his consulting career at Ernst & Young as a Senior Manager specializing in Reimbursement, Revenue recognition, and Reserve accounting. While at E&Y he earned his Master's Degree in Professional Accounting. Bryan was subsequently recruited by Coopers and Lybrand (now PwC) to help build a Healthcare Consulting Practice. As one of the "Founding Fathers" of the practice Bryan has held numerous leadership positions within PwC including Regional and National Practice Leader. In addition to driving organic growth, Bryan led the acquisition team responsible for acquiring a 100 person consulting practice in the Mid-West, helping to set the platform for what is now a Billion dollar healthcare consulting business, working with leading clients in the Provider, Payor and Life Science Industries. In addition to

recruiting and other business building activities, Bryan continued consulting with his clients in the areas of business operations, strategy, regulatory and compliance issues.

Bryan joined NMI's Board of Directors on July 1st, 2014 and will capitalize on his 30 years of Health Industry and accounting related experience to help lead NMI in its continued growth.

About NMI

NMI is dedicated to designing, investigating, developing, and commercializing life-saving novel nanomedicines for the treatment of ovarian cancer and other unmet medical needs. Ultimately, NMI's products will be part of the personalized medicine revolution occurring in cancer therapies. Our unique focus on reducing the complex nature of nanomedicine manufacturing is expected to enhance the speed by which we translate novel therapeutics to the clinic. As a participant in the National Cancer Institute's Centers for Cancer Nanotechnology Excellence, we are building a state of the art biomanufacturing facility as a national resource for nanomedicine and emerging biopharmaceutical community. NMI was founded in 2008 and is based in Worcester, Massachusetts. For more information, please visit <http://www.nemucore.com>.

Forward-looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.